- Home
- MLNK vs ANIP Comparison
MLNK vs ANIP Comparison
Compare MLNK & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- ANIP
- Stock Information
- Founded
- MLNK 1998
- ANIP 2001
- Country
- MLNK United States
- ANIP United States
- Employees
- MLNK N/A
- ANIP N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- ANIP Health Care
- Exchange
- MLNK Nasdaq
- ANIP Nasdaq
- Market Cap
- MLNK 1.5B
- ANIP 1.2B
- IPO Year
- MLNK 2021
- ANIP N/A
- Fundamental
- Price
- MLNK $18.78
- ANIP $68.02
- Analyst Decision
- MLNK Hold
- ANIP Strong Buy
- Analyst Count
- MLNK 7
- ANIP 8
- Target Price
- MLNK $21.64
- ANIP $79.75
- AVG Volume (30 Days)
- MLNK 262.5K
- ANIP 361.8K
- Earning Date
- MLNK 03-06-2025
- ANIP 05-09-2025
- Dividend Yield
- MLNK N/A
- ANIP N/A
- EPS Growth
- MLNK N/A
- ANIP N/A
- EPS
- MLNK N/A
- ANIP N/A
- Revenue
- MLNK $316,298,000.00
- ANIP $614,376,000.00
- Revenue This Year
- MLNK $7.59
- ANIP $27.62
- Revenue Next Year
- MLNK $8.13
- ANIP $7.71
- P/E Ratio
- MLNK N/A
- ANIP N/A
- Revenue Growth
- MLNK 4.18
- ANIP 26.20
- 52 Week Low
- MLNK $16.49
- ANIP $52.50
- 52 Week High
- MLNK $25.33
- ANIP $70.00
- Technical
- Relative Strength Index (RSI)
- MLNK 45.22
- ANIP 66.14
- Support Level
- MLNK $18.24
- ANIP $65.28
- Resistance Level
- MLNK $19.57
- ANIP $69.33
- Average True Range (ATR)
- MLNK 0.42
- ANIP 2.32
- MACD
- MLNK -0.07
- ANIP 0.29
- Stochastic Oscillator
- MLNK 37.07
- ANIP 83.54
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.